Three-year safety and clinical outcomes from the PD-1101 trial of AADC gene therapy for advanced Parkinson’s disease
Objective: To present preliminary 3-year data from the PD-1101 trial of VY-AADC01 for advanced Parkinson’s disease (PD) with motor fluctuations. Background: This 3-year phase 1b…AADC gene therapy administered via a posterior approach: 18-month results from the PD-1102 trial in advanced Parkinson’s disease
Objective: To report 18-month safety and clinical outcomes from a phase 1, open-label trial of VY-AADC01 (NBIb-1817) for Parkinson’s disease (PD) patients with motor fluctuations.…A Case of Improved Psychotic Depression and Motor Symptoms in Parkinson’s Disease following Electroconvulsive Therapy (ECT)
Objective: To describe a case of motoric, affective, and psychotic symptoms improving in PD following ECT. Background: Parkinson’s disease (PD) is a neurodegenerative disease caused…Impedance Doesn’t Change with Levodopa Treatment
Objective: We aimed to evaluate the impedance of patients on their best ON/worst OFFs with levodopa, assuming that the level of dopamine at electrode’s vicinity…Preclinical pharmacology and early clinical development of dopamine D1 positive allosteric modulators (D1PAMs) with therapeutic potential for neuropsychiatric disorders
Objective: The objective was to characterize novel dopamine D1PAMs pre-clinically in behavioral and neurochemical models and in phase 1 human studies in healthy volunteers and…How Parkinson’s Disease Affects Working Memory
Objective: Our study designed to (1) measure working memory via verbal Digit Span in Parkinson’s patients without mild cognitive impairment (MCI) (2) determine how dopaminergic…Neuroprotective propensity of marmelosin against 6-OHDA-induced cognitive impairment and apoptosis via upregulation of PI3K/Akt pathway
Objective: Current study was designed to explore the neuroprotective effect of marmelosin against apoptosis caused by 6-hydroxydopamine (6-OHDA) by upregulating phosphoinositide 3-kinase (PI3K)/protein kinase B…The study of the role of genetic risk factors in levodopa-induced dyskinesia development in Russian patients with Parkinson’s disease: a pilot study
Objective: The aim of our study is to search for genetic risk factors for the development of motor side effects of dopaminergic therapy, such as…Screening of mutations in PARK2 gene and Dopamine levels in Parkinson’s disease (PD) patients in Coimbatore population, India
Objective: The aim of the present study was to perform the mutational screening of PARK2 gene and dopamine level in PD patients of Coimbatore population,…Look Again: The Diagnostic Value of Repeat Dopamine Transporter Imaging
Objective: To demonstrate value and clinical significance of repeated and longitudinal 123I-FP-CIT SPECT dopamine transporter imaging (DaTscan) with quantitative data analysis for clinical use. Background:…
- « Previous Page
- 1
- …
- 6
- 7
- 8
- 9
- 10
- …
- 24
- Next Page »